Methyl 4-methyl-4,4a,5,13,14,14a-hexahydro-6lambda~5~-indolo[2,3-a]pyrano[3,4-g]quinolizine-1-carboxylate hydrochloride

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: Methyl 4-methyl-4,4a,5,13,14,14a-hexahydro-6lambda~5~-indolo[2,3-a]pyrano[3,4-g]quinolizine-1-carboxylate hydrochloride
• 英文别名: methyl 16-methyl-17-oxa-3,13-diazapentacyclo[11.8.0.02,10.04,9.015,20]henicosa-1,3,5,7,9,11,18-heptaene-19-carboxylate
• 化学式: C₂₁H₂₀N₂O₃
• 分子量: 348.4
• InChiKey: WYTGDNHDOZPMIW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  26
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  53.4
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• [EN] ALSTONINE DERIVATIVES AND SALTS THEREOF<br/>[FR] DÉRIVÉS D'ALSTONINE ET LEURS SELS
  申请人：[en]NAPO PHARMACEUTICALS, INC.

  公开号：WO2022266112A1

  公开（公告）日：2022-12-22

  The present disclosure is concerned with alstonine, alstonine analogs, and salts thereof for the treatment of various disorders where changes in 5-HT2A/5-HT2Creceptor signaling and/or dopamine transporter activity may be beneficial such as, for example, psychotic disorders, epilepsy, and anxiety disorders. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.